Related references
Note: Only part of the references are listed.Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
Olfa Khalifa et al.
SCIENTIFIC REPORTS (2022)
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial
Anat Yaskolka Meir et al.
GUT (2021)
A review of non-alcoholic fatty liver disease in non-obese and lean individuals
Mitra Ahadi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani et al.
METABOLITES (2021)
Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk
Anita M. van den Hoek et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Jamy Ard et al.
ADVANCES IN THERAPY (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
Chloe Wong et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
Chance S. Friesen et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
FXR in liver physiology: Multiple faces to regulate liver metabolism
Katrin Panzitt et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
Khaoula Errafii et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease
Eun Ju Cho et al.
SCIENTIFIC REPORTS (2021)
Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease
Tahar Hajri et al.
CELLS (2021)
The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease A Systematic Review and Meta-Analysis
Yiwen Shi et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2020)
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression
Lu Li et al.
REDOX BIOLOGY (2020)
Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes
Jingya Lyu et al.
MOLECULAR METABOLISM (2020)
Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review
Christina N. Katsagoni et al.
NUTRIENTS (2020)
Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
Hiroaki Yokomori et al.
BMJ OPEN GASTROENTEROLOGY (2020)
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Areti Sofogianni et al.
WORLD JOURNAL OF HEPATOLOGY (2020)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease
Jose M. Mato et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
Juliette Mouries et al.
JOURNAL OF HEPATOLOGY (2019)
Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism
Sophie A. Montandon et al.
SCIENTIFIC REPORTS (2019)
Non-alcoholic fatty liver disease in lean individuals
Somaya Albhaisi et al.
JHEP REPORTS (2019)
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
David Hojland Ipsen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
Dimitrios Oikonomou et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Zobair M. Younossi et al.
HEPATOLOGY (2018)
Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR
Kavita Jadhav et al.
MOLECULAR METABOLISM (2018)
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Liver X receptors link lipid metabolism and inflammation
Ira G. Schulman
FEBS LETTERS (2017)
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
Leon A. Adams et al.
GUT (2017)
A Novel Interacting Protein SERP1 Regulates the N-Linked Glycosylation and Function of GLP-1 Receptor in the Liver
Yuanyuan Xiao et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2017)
Treatment of NAFLD with diet, physical activity and exercise
Manuel Romero-Gómez et al.
JOURNAL OF HEPATOLOGY (2017)
Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics
Melania Manco
CHILDREN-BASEL (2017)
Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators
Juan Decara et al.
BIOFACTORS (2016)
Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice
Camella G. Wilson et al.
ENDOCRINOLOGY (2016)
Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease
Mohammad J. Alkhatatbeh et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo et al.
PLOS ONE (2016)
PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation
Qian Gao et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa
Eleonora Distrutti et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index
Qing Pang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling
Ayaka Ito et al.
ELIFE (2015)
Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis
Yang Jiao et al.
ACTA PHARMACOLOGICA SINICA (2015)
Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
Yongjie Ma et al.
PHARMACEUTICAL RESEARCH (2013)
Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
Seung-Hoi Koo
CLINICAL AND MOLECULAR HEPATOLOGY (2013)
Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease
Yuan Liu et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C
Elena Lima-Cabello et al.
CLINICAL SCIENCE (2011)
Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction
Paulina Pettinelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis
Gianluca Svegliati-Baroni et al.
LIVER INTERNATIONAL (2011)
Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice
Kristiaan Wouters et al.
FEBS LETTERS (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
Adam M. Deane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity
Debby P. Y. Koonen et al.
DIABETES (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Liver X receptors as integrators of metabolic and inflammatory signaling
N Zelcer et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
J Larsen et al.
DIABETES CARE (2001)
Peroxisomal beta-oxidation and steatohepatitis
MS Rao et al.
SEMINARS IN LIVER DISEASE (2001)